Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sentences Handed Down in Topamax Case

By Drug Discovery Trends Editor | May 24, 2010

BOSTON (AP) – A federal judge in Boston has ordered two subsidiaries of pharmaceutical giant Johnson & Johnson to pay more than $81 million after pleading guilty to illegally promoting the epilepsy drug Topamax for psychiatric uses.

Ortho-McNeil Pharmaceutical LLC will pay a $6.14 million criminal fine after pleading guilty Friday to one count of misdemeanor violation of the Food, Drug and Cosmetic Act for promoting Topamax for unproved uses.

Its holding company, Titusville, N.J.-based Ortho-McNeil-Janssen Pharmaceuticals Inc., will pay $75.37 million to resolve civil allegations under the False Claims Act.

Prosecutors say OMJPI hired outside physicians to join sales representatives in visits to health care providers and to speak at meetings and dinners about prescribing Topamax for unproved uses.

The sentence resolves a probe that began in 2003.

Date: May 24, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

New gonorrhea antibiotic could treat resistant infections
In door grow hemp. Cannabis at the beginning of flowering. Legal Marijuana cultivation in the home. Green background of leaves. Young cannabis plant. Medicinal indica with CBD.
Why Schedule III cannabis could be a win for Big Pharma
Red blood cells macro over red eritrosit background. Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Platelet-inspired nanoparticle delivers drugs directly where they are needed
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE